2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
5
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Colorectal Neoplasms
3
Sarcoma
2
Recurrence
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Stage IIIb and IV Non Small Cell Lung Cancer
1
Solid Tumor, Adult
1
Rare Diseases
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplastic Syndromes, Hereditary
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Microsatellite Instability
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Head and Neck Neoplasms
1
Genetic Predisposition to Disease
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Medullary
1
COVID-19
1
Biliary Tract Neoplasms
1
Interventions
Metformin
2
Leuprolide
2
Collagenases
2
Clomiphene
2
tremelimumab
1
durvalumab
1
Temozolomide
1
Streptozocin
1
Spironolactone
1
Specimen Handling
1
Radiosurgery
1
Radiation
1
Propofol
1
Prednisone
1
Plasma Exchange
1
Nivolumab
1
Midazolam
1
Mercaptopurine
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Ipilimumab
1
Infliximab
1
Immunoglobulins
1
High-Throughput Nucleotide Sequencing
1
Heavy Ion Radiotherapy
1
Fentanyl
1
FANG vaccine
1
Data Collection
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rare Diseases
×
High-Throughput Nucleotide Sequencing
×
Clear all
NCT06060184
2023-09-29
IonGER
University Hospital Tuebingen
Phase NA
Not yet recruiting
500 enrolled